Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Nano-Liposome Vaccine Carrying E75, a Her-2/Neu-Derived Peptide, Exhibits Significant Antitumour Activity in Mice Publisher Pubmed



Arab A1, 2, 3 ; Behravan J1, 2 ; Razazan A4 ; Gholizadeh Z5 ; Nikpoor AR6 ; Barati N1, 2, 3 ; Mosaffa F1, 2 ; Badiee A3, 7 ; Jaafari MR3, 7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  2. 2. Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
  3. 3. Nanotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
  4. 4. Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Immunogenetic and Cell Culture Department, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  6. 6. Department of Immunology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
  7. 7. Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Source: Journal of Drug Targeting Published:2018


Abstract

E75 (HER-2/neu-369–377), is an immunogenic peptide which is highly expressed in breast cancer patients. The purpose of this study was to develop an effective vaccine delivery/adjuvant system by attachment of this peptide to the surface of liposomes consisting of phospholipids including distearoylphosphocholine (DSPC) and distearoyl phosphoglycerol (DSPG) with high transition temperature (Tm) and dioleoylphosphatidylethanolamine (DOPE) (a pH-sensitive lipid for cytosolic antigen delivery) to improve antitumour immune activity against the E75 peptide. For this purpose, the E75 peptide was incorporated into liposomes consisting of DSPC/DSPG/cholesterol (Chol)/DOPE (15/2/3/5 molar ratio) through conjugation with distearoylphosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (maleimide-PEG 2000 -DSPE). Immunization of BALB/c mice was performed three times with different forms of liposomal formulations at 2-week intervals and antitumour immunity responses were evaluated. Results of ELISpot and flow cytometry analysis showed that mice vaccinated with DSPC/DSPG/Chol/DOPE/E75 have significantly enhanced the antigen-specific IFN-γ response of CD8 + T cells and generated cytotoxic T lymphocytes (CTL) antitumour responses. CTL responses induced by this formulation resulted in inhibition of tumour progression and longer survival time in the mice TUBO tumour model. The results revealed that the liposomes consist of DSPC/DSPG/Chol/DOPE could be suitable candidates for vaccine delivery of E75 peptide for the prevention and therapy of HER2-positive breast cancer and merit further investigation. © 2017 Informa UK Limited, trading as Taylor & Francis Group.
Related Docs
View other Related Docs
1. Preparation of Nanoliposomes Containing Her2/Neu (P5+435) Peptide and Evaluation of Their Immune Responses and Anti-Tumoral Effects As a Prophylactic Vaccine Against Breast Cancer, PLoS ONE (2020)
2. Application of E75 Peptide Vaccine in Breast Cancer Patients: A Systematic Review and Meta-Analysis, European Journal of Pharmacology (2018)
3. P435 Her2/Neu-Derived Peptide Conjugated to Liposomes Containing Dope As an Effective Prophylactic Vaccine Formulation for Breast Cancer, Artificial Cells# Nanomedicine and Biotechnology (2019)
4. Conjugated Nanoliposome With the Her2/ Neu-Derived Peptide Gp2 As an Effective Vaccine Against Breast Cancer in Mice Xenograft Model, PLoS ONE (2017)
5. Liposomal Gp100 Vaccine Combined With Cpg Odn Sensitizes Established B16f10 Melanoma Tumors to Anti Pd-1 Therapy, Iranian Journal of Basic Medical Sciences (2020)
6. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
7. Recent Progress in Immunotherapy of Breast Cancer Targeting the Human Epidermal Growth Factor Receptor 2 (Her2), Journal of Oncology Pharmacy Practice (2021)
8. Lambda Phage Nanoparticles Displaying Her2-Derived E75 Peptide Induce Effective E75-Cd8+ T Response, Immunologic Research (2018)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (4)
Seyed Mahdi Rezayat Sorkhabadi (2)
Other Related Docs
9. Cancer Immunology, Encyclopedia of Infection and Immunity (2022)
10. Delivery Systems for Leishmania Vaccine Development, Expert Review of Vaccines (2016)
11. Nanoliposomes Carrying Her2/Neu-Derived Peptide Ae36 With Cpg-Odn Exhibit Therapeutic and Prophylactic Activities in a Mice Tubo Model of Breast Cancer, Immunology Letters (2017)
12. Candidate Cancers for Vaccination, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
13. Improved Drug Delivery and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin by Targeting Anti-Her2 Peptide in Murine Breast Tumor Model, European Journal of Pharmaceutical Sciences (2016)
14. Docetaxel in Combination With Metformin Enhances Antitumour Efficacy in Metastatic Breast Carcinoma Models: A Promising Cancer Targeting Based on Pegylated Liposomes, Journal of Pharmacy and Pharmacology (2022)
15. Therapeutic Efficacy of Cisplatin Thermosensitive Liposomes Upon Mild Hyperthermia in C26 Tumor Bearing Balb/C Mice, Molecular Pharmaceutics (2017)
16. 5Tr1 Aptamer-Pegylated Liposomal Doxorubicin Enhances Cellular Uptake and Suppresses Tumour Growth by Targeting Muc1 on the Surface of Cancer Cells, Artificial Cells# Nanomedicine and Biotechnology (2018)
17. Candidate Cancers for Vaccination, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)